To help facilitate access to our nation’s nearly 70,000 retail pharmacies, PBMs are actively providing information to RxOpen, a central hub created after Hurricane Katrina to help promote uniform, consistent supply-chain information for stakeholders. PBMs also are supporting policy
Today, Thursday March 9, The Hill is hosting an important conversation titled: “Prescription for Change: Improving Competition to Lower Drug Prices,” featuring: David Schweikert (R-AZ), Member, Ways & Means Committee Tina Smith (D-MN), Member, Senate HELP Committee Lauren Aronson, Executive
Voices from around the nation, including small business owners and concerned citizens, have sounded the alarm on proposals targeting pharmacy benefit companies in Congress, specifically how policies would lead to increased health care costs for consumers, patients, and families, and
Bank of America (BofA) recently released the findings of an employer survey that found that the pharmacy benefit marketplace is highly competitive, confirmed that surveyed employers believe their pharmacy benefit company is transparent to them, and underscored the savings, flexibility,
(Washington, D.C) — Pharmaceutical Care Management Association (PCMA) Vice President of Policy Claire Wulf Winiarek has been selected as a member of the National Academy of Social Insurance (NASI), an organization dedicated to increasing public understanding of how social insurance contributes to
As Congress considers anti-PBM legislation in the new year, it is important lawmakers are aware that allowing the government to dictate the winners and losers in the health care system, according to policymakers and experts, will do nothing to actually
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott released the following statement on new National Health Expenditure (NHE) data from the Centers for Medicare & Medicaid Services: “The latest National Healthcare Expenditure data from CMS offers
The so-called “delinking” policy made news last week with the introduction of H.R. 6283. Among several glaring problems — including a rejection of free market performance-based incentives that lower drug costs for consumers — if enacted, “delinking” would hand a
See topline points from the “National Survey of Seniors Regarding the Medicare Part D Prescription Drug Benefit”
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on new National Health Expenditure (NHE) data from the Centers for Medicare & Medicaid Services: The latest NHE survey shows that the retail prescription drug net price index declined
©2024 PCMA. All Rights Reserved.
